<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162485</url>
  </required_header>
  <id_info>
    <org_study_id>3106009</org_study_id>
    <nct_id>NCT02162485</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus</brief_title>
  <official_title>Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µG/Inhalation; A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study is to compare the test products Salmeterol/fluticasone Easyhaler
      with marketed product Seretide Diskus in terms of the drug absorbed into the blood stream
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of plasma salmeterol and fluticasone propionate</measure>
    <time_frame>within 34 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt of plasma salmeterol and fluticasone propionate</measure>
    <time_frame>34 h</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Salmeterol/fluticasone Easyhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salmeterol/fluticasone Easyhaler with charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Seretide Diskus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus with charcoal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/fluticasone Easyhaler</intervention_name>
    <arm_group_label>Salmeterol/fluticasone Easyhaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol/fluticasone Easyhaler with charcoal</intervention_name>
    <arm_group_label>Salmeterol/fluticasone Easyhaler with charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus</intervention_name>
    <arm_group_label>Seretide Diskus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus with charcoal</intervention_name>
    <arm_group_label>Seretide Diskus with charcoal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained

          -  Good general health ascertained by detailed medical history, and laboratory and
             physical examinations

        Exclusion Criteria:

          -  Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,
             GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease within the
             previous 2 years

          -  Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study. As an
             exception, paracetamol and ibuprofen for occasional pain are allowed

          -  Known hypersensitivity to the active substance(s) or the excipient (lactose, which
             contains small amounts of milk protein) of the drug

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merja Mäkitalo</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leena Mattila, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orion Pharma Clinical Pharmacology Unit, Espoo, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orion Pharma Pharmacology Unit</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

